You've never seen anything like it · Doors open inStarts at 7:00 PM ET
Skip to content

Research peptide · Cellular research

FOXO4-DRI

Also known as proxofim · FOXO4 D-retro-inverso peptide

A designed D-retro-inverso peptide built from the FOXO4 forkhead domain, used as a research tool against the FOXO4 and p53 protein interaction.

Compound type
Research peptide
Research area
Cellular
Formula
C228H388N86O64
Average mass
5,358.058 Da
Monoisotopic mass
5,354.975 Da

What it is

FOXO4-DRI is a synthetic peptide designed as a competitor of a protein-protein interaction. Its molecular formula is C228H388N86O64, its average mass is 5358.06 g/mol and its monoisotopic mass is 5354.98. It is indexed as PubChem CID 167312269 and has also been named proxofim.

The parent sequence comes from the forkhead domain of the transcription factor FOXO4, which binds the transactivation domain of p53, and the peptide was built to occupy that interface 1.

Discovery and origin

The molecule was created for a 2017 study at Erasmus University Medical Center in Rotterdam, which designed it from the FOXO4 forkhead sequence and tested it in cultured cells and in mice 1. It is fully synthetic: no native protein contains this chain, because the retro-inverso design inverts both residue order and stereochemistry.

Structure and chemistry

A D-retro-inverso peptide is assembled from D-amino acids in reverse sequence order. The side chains then project in approximately the same spatial arrangement as in the parent L-peptide while the backbone amide bonds run the other way, which preserves much of the interaction surface and makes the chain a poor substrate for proteases that recognize L-residues.

At about 5.4 kDa the molecule is handled as a polycationic polypeptide rather than a small organic compound. Solid-phase synthesis at this length is demanding, and deletion and truncation sequences are the dominant process impurities. Material is isolated as an acetate or trifluoroacetate salt.

How it is studied in the laboratory

The founding study used cultured senescent cell models with viability, apoptosis and microscopy readouts, alongside mouse experiments in aged and chemotoxicity-exposed animals; the authors reported targeted apoptosis of senescent cells and attributed it to interference with the FOXO4 and p53 interaction 1.

Biophysical work has since addressed the target directly. A 2025 study using NMR spectroscopy and binding measurements mapped the interaction and reported that the disordered transactivation domain of p53 is the binding site for both FOXO4 and the peptide 2. Cell-based follow-up work has applied the peptide to cultured senescent fibroblast models, with apoptosis assays and subcellular localization of phosphorylated p53 as the readouts 3.

Analytical notes

Identity is confirmed by liquid chromatography with mass spectrometry in positive ion mode. At this mass the useful signals are the multiply charged series, with expected ions near m/z 1786.00 for [M+3H]3+, 1339.75 for [M+4H]4+ and 1072.00 for [M+5H]5+. Charge-state deconvolution, not a single peak, is the practical identity check.

Purity is assessed by reversed-phase HPLC. Ordinary amino acid analysis cannot distinguish the D-retro-inverso chain from its L-parent, so chiral analysis after hydrolysis, or comparison of retention against an authentic standard, is what confirms the intended stereochemistry.

Storage and handling in the laboratory

As supplied, the material is a lyophilized powder, stored at -20 degrees Celsius, sealed and protected from light. The lyophilized state is hygroscopic, so a sealed vial should reach room temperature before opening.

Open questions in the literature

No experimental structure of the peptide bound to p53 has been published, so the binding geometry is inferred from NMR and modeling rather than observed at atomic resolution 2. How well the cell and mouse findings generalize across senescence models is not systematically mapped, and quantitative data on the chain's stability under assay conditions are sparse.

Identity check

A mass-spectrometry result for FOXO4-DRI should show peaks near these values. A result more than about one unit away is worth a question to the testing lab. Salt forms such as acetate or TFA do not move these peaks, though they do mean less peptide in each milligram of powder.

IonExpected m/z
[M+3H]3+1786.00
[M+4H]4+1339.75
[M+5H]5+1072.00

References

  1. Baar MP, Brandt RMC, Putavet DA, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. 2017;169(1):132-147.e16. doi:10.1016/j.cell.2017.02.031. Source
  2. Bourgeois B, Spreitzer E, Platero-Rochart D, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature Communications. 2025;16(1):5672. doi:10.1038/s41467-025-60844-9. Source
  3. Kong YX, Li ZS, Liu YB, et al. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Communications Biology. 2025;8(1):299. doi:10.1038/s42003-025-07738-0. Source

For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease.